Position of the Transparency Council – Mestinon Retard (pyridostigmini bromidum) and Mestinon (pyridostigmini)

At its meeting on 7 April 2025, the Transparency Council adopted position No. 40/2025 on the validity of granting authorizations for the reimbursement of medicinal products Mestinon Retard (pyridostigmini bromidum) and Mestinon (pyridostigmini) in the indication: myasthenia

Publication of the position >>